Investor Presentaiton

Continuously Strong Support from Globally Renowned Investors Total fundraising since inception: US$ 2.6bn+ The largest IPO fund raise at the time for pre-revenue biopharmaceutical company Strong support from globally renowned investors from pre- IPO to post-IPO Pre-IPO Fund Raising Total follow-on offering: ~US$ 1.6bn The first and only HK biotech 18A with successful 4 rounds follow-on Industry Leader Receives More Attention and Focus by Capital Markets US$ 562m Lilly Asia Ventures Fidelity 礼来亚洲基金 TEMASEK HOLDINGS CAPITAL GROUP SDIC 国投创新 HILLHOUSE CAPITAL GIC ROCK SPRINGS IPO Total Proceeds CORMORANT ASSET MANAGEMENT CAPITAL |理成 LEGEND 資産 CAPITAL Ally Bridge Group 君联资本 Greenwoods 景林 F Fidelity INTERNATIONAL PRIME CAPITAL OppenheimerFunds BlackRockⓇ US$ 485m Value Partners Invesco Investing through discipline Follow-on Offerings 13 中国平安 US$ 1.6bn 中国人寿 PING AN CHINA LIFE WELLINGTON MANAGEMENT SEQUOIA UBS Global Asset Management LAKE BLEU CAPITAL Innovent 清池资本 Confidential Copyright©2021 Innovent Biologics Continued interests and confidence of global investors Track record in value delivering Capability to exceed market expectations Removed "B" marker and was included in the Hang Seng Composite index and included in the Stock Connect 44

View entire presentation